Could new drug slow down deterioration of the brain?
The AMARANTH STUDY will test whether the experimental drug, AZD3293 [LY3314814], slows the worsening of Alzheimer’s disease, compared to a placebo given to patients with Mild Cognitive Impairment (MCI) or Early Alzheimer’s disease.
It’s for people aged between 55-85 and is being conducted at several places across the UK, as well as worldwide, to find out if this investigational drug is safe and effective in slowing down the progression of the disease.
What will the study be looking at?
In Alzheimer’s disease, plaques and tangles are created in the brain. They cause your brain to gradually work less well, which means you have difficulty in thinking, learning, and remembering things. The plaques are made out of a sticky substance called amyloid. The investigational drug, AZD3293, is designed to reduce the creation of substances that will eventually become amyloid, and it may therefore slow down the deterioration of the brain in people with early Alzheimer’s disease. This study will test if this actually occurs.
Who can take part in this study?
To join this study, you must have either experienced gradual and progressive change in memory function over more than 6 months, or been diagnosed with mild Alzheimer’s disease or Mild Cognitive Impairment. You will also need a ‘study partner’ who is likely to be your carer or a family member.
How does the study work?
Participants are put into one of three groups:
Group 1: lower-dose investigational drug
Group 2: higher-dose investigational drug
Group 3: placebo (which is a tablet that has no active drug in it).
This is a double-blind study which means neither the volunteer, their study partner or their doctor will know which of these study groups they are assigned. This is done to make sure the results of the study cannot be unfairly influenced by anyone.
How long will the study treatment last?
The study will last approximately two and a half years. It is divided into 3 parts:
Screening period: To assess whether you are eligible to take part in the study. This takes place over a period of about 8 weeks.
Study treatment period: During this 2 year period you will take your study medication each day and attend regular clinic visits with your study partner.
Follow-up period: You will come back to the study clinic for a follow-up visit around 4-6 weeks after you finish your study treatment.
There are 21 scheduled visits during the study; 17 will take place at the clinic and 4 will be conducted by telephone with you and/or your study partner.
Which research centres are currently running the study?
We’re currently looking for volunteers to take part at the Glasgow Memory Clinic Ltd, West London Mental Health NHS Trust, Imperial College Healthcare NHS Trust, Re:Cognition Health London, Sussex Partnership NHS Foundation Trust and MAC Plc Clinical Research in Greater Manchester, Blackpool, Cannock and Leeds.
You can hear from Alan Lenox-Smith, Senior Clinical Research Physician at Lilly UK as he talks about the Amaranth study and what it involves:
You can see if you are eligible for this study – and others around the nation by logging into your Join Dementia Research account. If you haven’t yet registered with Join Dementia Research, why not sign up today?